MYSZ vs XERS

For growth investors, Xeris Biopharma Holdings, Inc.

(XERS) is the stronger pick with 43. 7% revenue growth year-over-year, versus 18. 0% for My Size, Inc. (MYSZ). Xeris Biopharma Holdings, Inc. (XERS) offers the better valuation at 2071. 9x trailing P/E (55. 3x forward), making it the more compelling value choice. Analysts rate Xeris Biopharma Holdings, Inc. (XERS) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Xeris Biopharma Holdings, Inc.

(XERS) delivered a total return of +104. 0%, compared to -99. 8% for My Size, Inc. (MYSZ). Over 10 years, the gap is even starker: XERS returned -67. 2% versus MYSZ's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Xeris Biopharma Holdings, Inc.

(XERS) is the lower-risk stock at 1. 04β versus My Size, Inc. 's 1. 17β — meaning MYSZ is approximately 12% more volatile than XERS relative to the S&P 500. On balance sheet safety, My Size, Inc. (MYSZ) carries a lower debt/equity ratio of 4% versus 3% for Xeris Biopharma Holdings, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Xeris Biopharma Holdings, Inc.

(XERS) is pulling ahead at 43. 7% versus 18. 0% for My Size, Inc. (MYSZ). On earnings-per-share growth, the picture is similar: Xeris Biopharma Holdings, Inc. grew EPS 100. 9% year-over-year, compared to 78. 1% for My Size, Inc.. Over a 3-year CAGR, MYSZ leads at 298. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Xeris Biopharma Holdings, Inc.

(XERS) is the more profitable company, earning 0. 2% net margin versus -48. 4% for My Size, Inc. — meaning it keeps 0. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: XERS leads at 8. 5% versus -47. 8% for MYSZ. At the gross margin level — before operating expenses — XERS leads at 81. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Xeris Biopharma Holdings, Inc.

(XERS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 04)). Both have compounded well over 10 years (XERS: -67. 2%, MYSZ: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (MYSZ (Technology) and XERS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.